|
Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms |
Gauthier K, Bai A, Perras C, Cunningham J, Ahuja T, Richter T, Kovacs C |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Gauthier K, Bai A, Perras C, Cunningham J, Ahuja T, Richter T, Kovacs C. Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Evidence from six placebo-controlled randomized controlled trials revealed that denosumab and zoledronic acid reduced the risk of vertebral, hip, and non-vertebral fractures in postmenopausal women with osteoporosis. Raloxifene was associated with a reduced incidence of vertebral fractures, but evidence was limited regarding hip and non-vertebral fractures, suggesting that it may not be effective in preventing such outcomes. Harms data did not raise new safety concerns; however, specific harms profiles should be considered when selecting treatment. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Bone Density Conservation Agents; Diphosphonates; Imidazoles; Osteoporosis, Postmenopausals; Raloxifene Hydrochloride Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, K1S 5S8 Ottawa, Ontario Canada Email: htainfo@cadth.ca AccessionNumber 32012000711 Date abstract record published 02/10/2012 |
|
|
|